Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Gina Mazzariello Sells 8,828 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 8,828 shares of the stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $14.58, for a total value of $128,712.24. Following the transaction, the insider owned 148,141 shares of the company’s stock, valued at approximately $2,159,895.78. This trade represents a 5.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Amylyx Pharmaceuticals Trading Up 1.0%

Amylyx Pharmaceuticals stock opened at $13.42 on Friday. The stock has a market cap of $1.20 billion, a P/E ratio of -5.37 and a beta of -0.33. The stock has a 50 day moving average of $10.29 and a 200-day moving average of $7.00. Amylyx Pharmaceuticals, Inc. has a 52 week low of $2.60 and a 52 week high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, August 7th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.02). As a group, equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wall Street Zen upgraded Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, July 18th. Bank of America upped their price target on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday. The Goldman Sachs Group upped their price target on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, September 16th. Guggenheim upped their price target on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Finally, UBS Group raised Amylyx Pharmaceuticals to a “hold” rating in a research report on Tuesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $14.75.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at $28,000. Valeo Financial Advisors LLC acquired a new position in shares of Amylyx Pharmaceuticals during the first quarter valued at $35,000. R Squared Ltd increased its holdings in shares of Amylyx Pharmaceuticals by 99.9% during the first quarter. R Squared Ltd now owns 12,736 shares of the company’s stock valued at $45,000 after purchasing an additional 6,366 shares during the period. Ameritas Investment Partners Inc. acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at $45,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after purchasing an additional 5,904 shares during the period. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.